Literature DB >> 17387301

Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design.

Madhusmita Behera1, Ambuj Kumar, Heloisa P Soares, Lubomir Sokol, Benjamin Djulbegovic.   

Abstract

BACKGROUND: The randomized, controlled trial (RCT) is the "gold standard" for establishing the effect of any intervention. This approach, however, is often not feasible with rare diseases such as cutaneous T-cell lymphoma.
METHODS: We review the principles of evidence-based medicine to see which are particularly pertinent to the study of rare diseases.
RESULTS: When an RCT is not feasible, attention is given to determining all the available prior data. Evaluation of the new data and the historic base requires attention to biases, but can allow estimation of a "true" study result.
CONCLUSIONS: Even when an RCT cannot be performed because of insufficient cases, utilization of evidence-based methodology can help minimize bias and maximize the truth of observed new data.

Entities:  

Mesh:

Year:  2007        PMID: 17387301     DOI: 10.1177/107327480701400209

Source DB:  PubMed          Journal:  Cancer Control        ISSN: 1073-2748            Impact factor:   3.302


  12 in total

1.  Uncertainty and equipoise: at interplay between epistemology, decision making and ethics.

Authors:  Benjamin Djulbegovic
Journal:  Am J Med Sci       Date:  2011-10       Impact factor: 2.378

Review 2.  The National Clinical Trials Network: Conducting Successful Clinical Trials of New Therapies for Rare Cancers.

Authors:  Anne F Schott; John J Welch; Claire F Verschraegen; Razelle Kurzrock
Journal:  Semin Oncol       Date:  2015-07-10       Impact factor: 4.929

Review 3.  Disease registries and outcomes research in children: focus on lysosomal storage disorders.

Authors:  Simon Jones; Emma James; Suyash Prasad
Journal:  Paediatr Drugs       Date:  2011-02-01       Impact factor: 3.022

Review 4.  Publication bias in Kienböck's disease: systematic review.

Authors:  Lee Squitieri; Elizabeth Petruska; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2010-03       Impact factor: 2.230

Review 5.  Therapy of collagen VI-related myopathies (Bethlem and Ullrich).

Authors:  Luciano Merlini; Paolo Bernardi
Journal:  Neurotherapeutics       Date:  2008-10       Impact factor: 7.620

Review 6.  A theoretical framework for early human studies: uncertainty, intervention ensembles, and boundaries.

Authors:  Jonathan Kimmelman
Journal:  Trials       Date:  2012-09-22       Impact factor: 2.279

7.  Rare Cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper.

Authors:  P G Casali; P Bruzzi; J Bogaerts; J-Y Blay
Journal:  Ann Oncol       Date:  2014-10-01       Impact factor: 32.976

8.  Bayesian approach to the assessment of the population-specific risk of inhibitors in hemophilia A patients: a case study.

Authors:  Ji Cheng; Alfonso Iorio; Maura Marcucci; Vadim Romanov; Eleanor M Pullenayegum; John K Marshall; Lehana Thabane
Journal:  J Blood Med       Date:  2016-10-25

Review 9.  Using a meta-narrative literature review and focus groups with key stakeholders to identify perceived challenges and solutions for generating robust evidence on the effectiveness of treatments for rare diseases.

Authors:  Kylie Tingley; Doug Coyle; Ian D Graham; Lindsey Sikora; Pranesh Chakraborty; Kumanan Wilson; John J Mitchell; Sylvia Stockler-Ipsiroglu; Beth K Potter
Journal:  Orphanet J Rare Dis       Date:  2018-06-28       Impact factor: 4.123

10.  Clinical evidence for orphan medicinal products-a cause for concern?

Authors:  Eline Picavet; David Cassiman; Carla E Hollak; Johan A Maertens; Steven Simoens
Journal:  Orphanet J Rare Dis       Date:  2013-10-16       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.